Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go:
18
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Rnwl is aiming to be the first ever over-the-top insurance platform. The company asserts that conventional insurance companies rely on a lead generation business model that is archaic and inefficient. These result in a customer's insurance options becoming an expensive and time-consuming affair. Rnwl is endeavouring to simplify this. Users can enter their credentials and requirements on the Rnwl website. The company will analyse the market and suggest the best deals for the user. Rnwl has been accepted into the Financial Conduct Authority (FCA's) Innovation Hub. It will use 74% of the investment in human resource, 14% in marketing, and 12% as operational costs.
days to go:
Expired
investment:
£450,366
Rightangled is a healthcare technology company backed by NHS England & regulated by the Care Quality Commission (CQC). It began its journey as a platform that would enable the use of genetic information within the medical practice, in an accurate, streamlined, and affordable way. It gradually established itself as a healthcare provider for screening and diagnostic services. Its Heart DNA Test project, launched in 2017, is helping patients minimize their cardiac risks and enabling doctors to have a complete risk profile for their patients. The project was appreciated and received funding from NHS England. Its next project, Fitness DNA Test, tapped into the fitness and wellbeing markets. Recently, in the wake of the COVID-19 threat, the company has developed a home-based throat swab test to detect the viral infection, by testing viral load presented in its nucleic acid material within (RNA). For its efforts, Rightangled has been featured on CNN, Sky News, LBC radio, Sky News radio, and Newsweek. With the investment, the company aims to release a mobile application by the end of 2020, and develop an AI system to give instant tailored health, diet, and fitness advice to its users based on the data gathered from patient-doctor interactions and patient responses.
days to go:
Expired
investment:
£522,689
Celo is an app-based insurance provider designed to provide cheaper quotes, faster claims, and a pleasant user experience. We plan to offer insurance cover for motor vehicles, travel, health, and more. Like Monzo and Starling who are disrupting banking, Celo plans to disrupt the insurance industry.
days to go:
Expired
investment:
£142,840
Clim8 is a sustainable investment company which allows people to invest into clean energy and green companies According to the United Nations, the world needs to invest $2.4 trillion dollars, every year, into clean energy, from now until 2035, to meet the climate change targets. Clim8 aims to capitalise on this objective by building a simple way to invest in a targeted portfolio of publicly listed companies that are making an impact in sectors such as clean energy, clean technology, sustainable food, smart mobility, and recycling. The company has successfully raised a seed round of £650,000 in 2019 from investors with backgrounds in finance, including ex Morgan Stanley and Deutsche Bank executives. With the investment, the company plans to launch its proprietary app, invest in recruiting human resources and promote marketing activities to broaden the brand identity.
days to go:
Expired
investment:
£1,523,120
Clim8 is a financial technology company that aims to move billions of pounds of investment into sectors such as clean energy, clean technology, sustainable food, smart mobility, and recycling. It is authorised by the Financial Conduct Authority (FCA). The company quotes United Nations data arguing that the World needs to invest $2.4 trillion every year into clean energy, from now until 2035, to meet climate change targets. Clim8 aims to capitalise on this objective. It launched its app on iOS and Android in private beta in October 2020 and then in the App Store in March 2021. It claims that its users have invested from £25 up to £97,000. The company has raised £5 million in venture capital to date, secured up to £2 million in airtime for equity from Channel 4 Ventures, and garnered a 4.8 star rating in the App Store, from a cumulative 100 reviews. The company will use the investment to accelerate user acquisition and launch new product offerings including pensions.
days to go:
Expired
investment:
£2,849,790
